Pure H20 Bio-Technologies, Inc. Announces Engagement of WesCom Capital, Inc. to Manage Revenue Sharing Pilot Program

Pure H2O Bio-Technologies, Inc. (Pink Sheets: PRHB) is proud to announce it has�engaged Wescom Capital, Inc., to assist in the management, marketing and administration of Pure H20�s �Pilot Program.� The Company successfully completed its self underwritten financial program that offers an opportunity to selected and qualified professionals. Can now be viewed in it�s entirety on the Company�s web-site: www.pureh20biotech.com. The Company intends to file with the Securities and Exchange Commission Form D and related documents with the Division of Securities as deemed necessary under �Participant Revenue Sharing Agreement� (�PRSA�) for its first 100 manufactured Integrated Hospital Potable Water Disinfections System known as Model 7000.

Mr. Gary Schmidt, of WesCom Capital, stated, �We are very excited about the financial opportunity regarding the �Pilot Program� offered by PRHB. We look forward to assisting them in managing and marketing the program, as well as in bringing their product to the marketplace. With pharmaceutical waste spilling into our water supply, it is obvious that there is a growing demand for absolute clean water for hospital patients, including people with weakened immune systems. It is our opinion that the company�s product addresses that need and demand.�

The Pilot Program is designed to offer an opportunity that benefits all parties involved. It allows the Company to seek additional capital in the form of participants sharing revenues generated from intended lease, rental or purchase agreements; it allows the Company to seek capital through government financial assistance programs for skilled workers, equipment and expansion. It allows the commencement of manufacturing the first 100 Hospital Systems; it allows expediency in regard to our micro�team, engineering team, laboratories, government agencies and officials; it allows a financial opportunity for investors to receive conservative returns and allows the Company to absorb expenses associated with NSF Certification without further dilution to shareholders.

About Pure H20 Bio-Technologies, Inc.

Pure H2O recently completed its bench, kinetic and pre-certification testing of its innovative drinking water treatment system with outstanding results. Mr. Joseph Doxey, President of Pure H2O, stated, �The engagement of Wescom Capital is a major step in the Company�s move to raise capital via our Participant Revenue Sharing Agreement versus unfavorable equity sales. The Company will now join forces with Wes Com Capital, Inc., begin its marketing and sales campaign, targeting hospitals, nursing homes and medical facilities in need of pathogen-free and chemical-free water. On July 31, 2007, the Company was awarded patent #7250111, and has two additional patents pending at this time that are under review with the U.S. Patent and Trademark Office, Washington, D.C

About WesCom Capital, Inc.

Wescom Capital has assisted companies accelerate growth, streamline operations, and create new levels of customer and equity value in the following industries:

Wireline, Wireless and VOiP Telecommunications
Technology
Software
Electronic Funds Transfer
Publications
Fisheries
Environmental Cleanup and Compliance
Oil and Gas
International Trade

Visit our web-site at www.pureh20biotech.com.

The �Participant Revenue Sharing Agreement� (�PRSA�) can be viewed on the Company�s web-site under title �Pilot Program.� Further information has been uploaded for the serious professional including (i)Technical Production Video, (ii) Written Video Script, (iii) Question & Answers produced by Special Report T.V. and (iv) Description of the Hospital Disinfection System Model 7000.

To learn more about our Pilot Program or for additional questions call Mr. Gary Schmidt at Wescom Capital, Inc.�(206) 420-5710 or write to Mr. Schmidt via email at gls@wescomcapital.com.

The Company will be announcing its progress on a regular basis and will continue to keep its shareholders apprised through these stages. Visit our web-site for updates and to view our Pilot Program at www.pureh20biotech.com.

The foregoing press release contains forward-looking statements that can be identified by such terminology as "expects," "potential,� suggests," "may," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and completion in general. Forward-looking statements speak only as to the date they were made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Pure H2O Bio Technologies (CE) (USOTC:PRHB)
過去株価チャート
から 1 2025 まで 2 2025